Recurrent Glioblastoma Clinical Trial
Official title:
A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas
Verified date | June 2024 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the effect of multiple doses of NSC-CRAd-S-pk7 in treating patients with high-grade gliomas that have come back (recurrent). NSC-CRAd-S-pk7 consists of neural stem cells that carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | August 7, 2025 |
Est. primary completion date | August 7, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient must be age >= 18 years - Patient has a Karnofsky performance status of >= 70% - Patient has a life expectancy of >= 3 months - Patient has histologically-confirmed, diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, not otherwise specified [NOS]), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV) - Imaging studies show evidence of recurrent, supratentorial tumor(s). The presence of infratentorial tumor is allowed if the patient also has supratentorial disease that is amenable to placement of an intracavitary Rickham catheter - Patient's high-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide - The patient must be in need of surgery for tumor resection - Based on the neurosurgeon's judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles - Absolute neutrophil count (ANC) of >= 1000 cells/mm^3 - Platelet count >= 100,000 cells/mm^3 - Total bilirubin =< 2.0 mg/dl - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 4 times the institutional upper limit of normal - Serum creatinine =< the institutional upper limit of normal - At least 6 weeks must have elapsed since taking a nitrosourea-containing chemotherapy regimen - At least 4 weeks since completing a non-nitrosourea-containing cytotoxic chemotherapy regimen (except temozolomide: only an interval of 23 days is required from the last dose administered when patient has been recently treated with the standard temozolomide regimen of daily for 5 days, repeated every 28 days) - At least 2 weeks from taking the last dose of a targeted agent - At least 4 weeks from the last dose of bevacizumab - There is no limit to the number of prior therapies for enrollment during treatment schedule escalation; however, once the maximum tolerated treatment schedule has been identified further enrollment to complete the accrual goal of 12 participants treated at the maximum tolerated treatment schedule will be limited to glioblastoma patients at first or second recurrence - All participants must have the ability to understand and the willingness to sign a written informed consent - The effects of this treatment on a developing fetus are unknown. Therefore, female patients of childbearing potential and sexually-active male patients must agree to use an effective method of contraception while participating in this study. Women of childbearing potential must have a negative pregnancy test =< 2 week prior to registration Exclusion Criteria: - Patient has anti-human leukocyte antigen (HLA) antibodies specific for HLA Class I antigens (A*01, A*31, B*07, B*15, C*07) expressed by the neural stem cells - Patient is receiving radiation, chemotherapy, or another investigational agent - Patient has had prior therapy with neural stem cells - Patient has not recovered from any toxicity (> grade 1) of prior therapies, except alopecia - Patient is unable to undergo a brain MRI - Patient has chronic or active viral infections of the central nervous system (CNS) - Patient has a coagulopathy or bleeding disorder - Patient has an uncontrolled illness including ongoing or active infection - Patient has another active malignancy - Patient is pregnant or breastfeeding - A patient has a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | City of Hope Medical Center | Duarte | California |
United States | Standford University | Stanford | California |
United States | Wake Forest University | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | Assessed using the Common Terminology Criteria for Adverse Events version 5.0. | Up to 30 days post removal of Rickhams | |
Secondary | Neural Stem Cells-expressing CRAd-S-pk7 (NSC-CRAd-S-pk7) immunogenicity | Up to 30 days post removal of Rickhams | ||
Secondary | NSC-CRAd-S-pk7 migration within the brain | Up to 30 days post removal of Rickhams | ||
Secondary | NSC-CRAd-S-pk7 migration outside the brain | Up to 30 days post removal of Rickhams | ||
Secondary | Disease response | Response Assessment in Neuro-Oncology Criteria will be used to assess response on brain magnetic resonance imaging in all study participants who receive at least 80% of the planned doses of study treatment. Disease response will be similarly assessed for the cohort of 12 glioblastoma (GBM) participants at first or second recurrence who will be treated at the maximum tolerated number of cycles (MTC). | Up to 2 years | |
Secondary | Progression-free survival (PFS) | Will estimate the rate 90% confidence interval (CI) for PFS at 6 months and use Kaplan Meier methods to estimate median PFS for all study participants as well as for the cohort of 12 GBM participants at first or second recurrence who will be treated at the MTC. | From the time of surgery to the event date of progression, assessed at 6 months | |
Secondary | Overall survival (OS) | Will estimate the rate 90% CI for OS at 9 months and use Kaplan Meier methods to estimate median OS for all study participants as well as for the cohort of 12 GBM participants at first or second recurrence who will be treated at the MTC. | From time of surgery to date of death, assessed at 9 months | |
Secondary | Changes in HSPG and survivin expression | Changes in HSPG and survivin expression by immunohistochemistry IHC in pre- and post-treatment tissue to see if there is a relationship with disease response. | Baseline up to 2 years | |
Secondary | Changes in immune cell populations | Changes in immune cell populations in the tumor microenvironment in pre- and posttreatment tumor tissue samples will be assessed by Vectra Spectral Imaging. | Baseline up to 2 years | |
Secondary | Changes in tumor growth | Develop a biomathematical model for predicting tumor response to study treatment. | Baseline up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05577091 -
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05284643 -
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
|
N/A | |
Recruiting |
NCT05039281 -
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04988750 -
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
|
N/A | |
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 | |
Completed |
NCT03216499 -
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Not yet recruiting |
NCT04717999 -
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
|
N/A | |
Not yet recruiting |
NCT05540275 -
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT04044937 -
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
|
Phase 2 | |
Recruiting |
NCT04888611 -
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
Recruiting |
NCT05463848 -
Surgical Pembro +/- Olaparib w TMZ for rGBM
|
Phase 2 | |
Active, not recruiting |
NCT04479241 -
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT00777153 -
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
|
Phase 3 | |
Withdrawn |
NCT05017610 -
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
|
Early Phase 1 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT05324501 -
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT05666349 -
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
|
Phase 1 |